Novanta Inc. (NOVT): Price and Financial Metrics

Novanta Inc. (NOVT)

Today's Latest Price: $118.54 USD

0.03 (-0.03%)

Updated Dec 2 4:00pm

Add NOVT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

NOVT Stock Summary

  • NOVT's current price/earnings ratio is 101.48, which is higher than 91.82% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NOVT is currently 32.3, higher than 87.04% of US stocks with positive operating cash flow.
  • NOVT's price/sales ratio is 6.92; that's higher than the P/S ratio of 79.7% of US stocks.
  • Stocks that are quantitatively similar to NOVT, based on their financial statements, market capitalization, and price volatility, are VIAV, DIOD, PRGS, IPGP, and MRCY.
  • NOVT's SEC filings can be seen here. And to visit Novanta Inc's official web site, go to

NOVT Stock Price Chart Interactive Chart >

Price chart for NOVT

NOVT Price/Volume Stats

Current price $118.54 52-week high $127.91
Prev. close $118.57 52-week low $66.44
Day low $115.79 Volume 79,365
Day high $118.99 Avg. volume 124,427
50-day MA $113.32 Dividend yield N/A
200-day MA $100.31 Market Cap 4.17B

Novanta Inc. (NOVT) Company Bio

Novanta Inc. designs, develops, manufactures, and sells precision photonic and motion control components, and subsystems to original equipment manufacturers in the medical equipment and advanced industrial technology markets. The company operates through three segments: Laser Products, Vision Technologies, and Precision Motion. The company was founded in 1968 and is based in Bedford, Massachusetts.

NOVT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$118.54$72.82 -39%

We started the process of determining a valid price forecast for Novanta Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novanta Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for NOVT, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 6.99 -- which is good for besting 61.05% of its peer stocks (US stocks in the Technology sector with positive cash flow).
  • 95% of the company's capital comes from equity, which is greater than 83.97% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 16% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Technology that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NOVT, try VRNT, ROG, CRUS, HQY, and ACN.

NOVT Latest News Stream

Event/Time News Detail
Loading, please wait...

NOVT Latest Social Stream

Loading social stream, please wait...

View Full NOVT Social Stream

Latest NOVT News From Around the Web

Below are the latest news stories about Novanta Inc that investors may wish to consider to help them evaluate NOVT as an investment opportunity.

New MOVIA 2-Axis Scan Head Complements Laser Beam-Steering Portfolio

BEDFORD, Mass.--(BUSINESS WIRE)-- #CambridgeTechnology--New MOVIA 2-axis scan head from Cambridge Technology, a business unit of Novanta, is compatible with a majority of lasers for processing materials.

Business Wire | September 9, 2020

New Handheld Scanner Integrates LF/HF RFID and 1D/2D Barcode

SYRACUSE, N.Y.--(BUSINESS WIRE)-- #InnovationsThatMatter--JADAK, a business unit of Novanta, launches the HS-1RS Secure Access Handheld Barcode Scanner, enabled with software from Imprivata and HID.

Business Wire | August 26, 2020

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q2 2020 Results - Earnings Call Transcript

Novanta, Inc. (NOVT) Q2 2020 Earnings Conference Call August 06, 2020 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Joe Jagoda - CJS Securities Rick Eastman - Robert W. Baird Brian Drab...

SA Transcripts on Seeking Alpha | August 9, 2020

Novanta Announces Financial Results for the Second Quarter 2020

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2020. Financial Highlights Three Months Ended (In millions, except per share amounts) July 3, June 28, 2020 2019 GAAP Revenue $ 144.7 $ 155.1 Operating Income $ 13.7 $ 15.1 Consolidated Net Income $ 11.7 $ 10.4 Diluted EPS $ 0.3

Business Wire | August 6, 2020

Analysts Estimate Novanta (NOVT) to Report a Decline in Earnings: What to Look Out for

Novanta (NOVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Read More 'NOVT' Stories Here

NOVT Price Returns

1-mo 6.87%
3-mo 13.83%
6-mo 4.61%
1-year 33.72%
3-year 154.38%
5-year 718.08%
YTD 34.03%
2019 40.38%
2018 26.00%
2017 138.10%
2016 54.19%
2015 -7.47%

Continue Researching NOVT

Want to see what other sources are saying about Novanta Inc's financials and stock price? Try the links below:

Novanta Inc (NOVT) Stock Price | Nasdaq
Novanta Inc (NOVT) Stock Quote, History and News - Yahoo Finance
Novanta Inc (NOVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8881 seconds.